Today, inhibitors of EGFR, ALK, PI3K/AKT/mTOR, RAS-MAPK, RET, MET, BRAF, and NTRK/ROS1, as well as PD1 and CTLA4 molecules, are available for NSCLC, and many of these are now typical of care for selected patients (Fig. 1). The gene discussed is MTOR; the disease is non-small cell lung carcinoma.